Search results for: Innovation Policy Prize
Filter search results
Competition through Innovation, Innovation through Competition
1 November 1998
…henceforth referred to as ‘incremental innovations’ to distinguish them from ‘breakthrough innovations’. According to such criticisms, the prevalence of a ‘me-too’ R&D strategy would have three serious negative implications: 1….
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
…pharmaceutical research and development and biopharmaceutical innovation. In this blog we discuss is detail why the assumptions in the CBO’s model are too uncertain to be useful for policymakers. A…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
7 September 2018
…Founder and Director of the UCL Institute for Innovation & Public Purpose (IIPP). She advises policy makers around the world on innovation-led inclusive growth, including a special advisory role to…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
27 September 2018, 11:00pm
…UCL Institute for Innovation & Public Purpose (IIPP). She advises policy makers around the world on innovation-led inclusive growth, including a special advisory role to the EC. She is winner…
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…and the development of pharmaceutical innovation. Consequently, factors and incentive systems that can reduce the pharmaceutical market size may negatively affect the R&D of pharmaceutical innovation. A report by Copenhagen…
One week left to register
20 August 2022
…Policy Prize Award Ceremony! Join us on 14 Dec as the winner is announced & they present their solution. Register for free: https://hubs.la/Q01xZ3LZ0 #AwardCeremony #HealthEconomics #InnovationPrize Read more on X….
Beyond opportunity cost: what are health systems for? The UK–US pharmaceutical agreement and the limits of QALY maximisation
23 October 2026
…broader considerations including industrial policy, economic growth and investment. Official policy already recognises that health maximisation is not the government’s sole objective. The real question, therefore, is not whether health…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
…on a narrow conception of biopharmaceutical innovation that continues to exclude post-approval innovation The CBO analysis gives an incomplete picture of the losses associated with reduced biopharmaceutical innovation. The only…
Does the New CBO Report Change Anything?
15 September 2021
…us to conclude that the CBO’s initial policy evaluation was an unreliable predictor of the impact of H.R. 3 on innovation and shouldn’t be used to guide policymaking, it is…